Slide Presentations: Wednesday, November 3, 2010 |

Thrombospondin-1 as a Biomarker in Pulmonary Hypertension FREE TO VIEW

Ralf H. Kaiser, MD; Christian Frantz; Robert Bals, PhD; Michael Böhm, PhD; Heinrike Wilkens, PhD
Author and Funding Information

UniversityHospital des Saarlandes, Homburg/Saar, Germany

Chest. 2010;138(4_MeetingAbstracts):893A. doi:10.1378/chest.10764
Text Size: A A A
Published online


PURPOSE: Vasorelaxation of pulmonary resistance vessels by a NO mediated accumulation of cGMP in the vascular smooth muscle cells is one of the main treatment principles of pulmonary hypertension (PH). The NO and VEGF pathway can be counteracted by the binding of thrombospondin-1 (TSP-1) to its receptors CD47 and CD36. TSP-1 is synthesized from both smooth muscle cells and endothelial cells under conditions of hypoxia or pathologically increased shearstress as found in PH. We examined the clinical relevance of TSP in patients with PH as a new pathophysiological concept and biomarker.

METHODS: After informed consent, blood was drawn in 62 patients with pulmonary hypertension, 15 of these patients underwent right heart catheterization with vasoreactivity testing for diagnostic reasons. Thrombocytes were stabilized by using CTAD tubes and then eliminated by centrifugation. We processed and measured levels of TSP-1, PDGF-BB and big-endothelin by ELISA according to vendor instructions. Twenty-one healthy subjects served as control.

RESULTS: Patients with pulmonary arterial hypertension (n=50) or chronic thromboembolic pulmonary hypertension (n=5) showed a significant elevation of TSP-1 (491±133 resp. 416±119ng/ml), PDGF-ββ (809±166 vs. 652±326pg/ml) and big-Endothelin (4.45±0.69 vs. 2.56±1.80pg/ml) as compared to the control group (n=21, TSP-1: 113±22ng/ml, PDGF-ββ: 279±107pg/ml, big-Endothelin: 1.35±0.37pg/ml). Patient with a PH related to COPD (n=5) showed a normal TSP-1 level (212±54ng/ml). Although the control group was slightly younger, there was no correlation of age and TSP-level. Furthermore, a trend of decreased circulating TSP was observed after ilomedin testing. No relationship between TSP-1 levels and hemodynamic parameters could be found.

CONCLUSION: This data suggest that pathological shearstress and chronic hypoxia lead to an induction of TSP-1 in pulmonary hypertension. While previous biomarkers focus on endothelial function or myocardial strain, we examined TSP-1 as a biomarker of shearstress for the first time.

CLINICAL IMPLICATIONS: Binding of TSP-1 to its receptor CD47 could interfere with therapies using the cGMP or PKG pathways. The predictive value of TSP-1 in pulmonary hypertension remains to be elucidated.

DISCLOSURE: Ralf Kaiser, No Financial Disclosure Information; No Product/Research Disclosure Information

08:00 AM - 09:15 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543